Overview

* Cumberland Q2 2025 revenue rises 10% yr/yr to $10.8 mln

* Year-to-date revenue up 23% over first half of 2024

* Co announces Vibativ 4-Vial Starter Pak availability through Vizient

Outlook

* Company expresses optimism for continued success in clinical programs

* Cumberland optimistic about building on first-half success

Result Drivers

* PRODUCT PORTFOLIO - FDA-approved brands contributed to a 10% revenue increase in Q2 2025

* VIBATIV AVAILABILITY - New supply arrangement with Vizient enhances Vibativ treatment flexibility

* CLINICAL PROGRESS - Phase II FIGHT DMD trial shows promising results for ifetroban in improving cardiac function

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $10.80

Revenue mln

Q2 $11.60

Operatin mln

g

Expenses

Analyst Coverage

* The one available analyst rating on the shares is "hold"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)